Literature DB >> 18171610

Autoantibody explosion in antiphospholipid syndrome.

Yehuda Shoenfeld1, Gilad Twig, Uriel Katz, Yaniv Sherer.   

Abstract

Antiphospholipid syndrome (APS) is characterized by thrombosis and pregnancy loss in the presence of antiphospholipid antibodies (aPL), mainly anticardiolipin, anti-beta2-glycoprotein I and lupus anticoagulant. However, similar to systemic lupus erythematosus, APS is also characterized by multiple other autoantibodies including 'non-classical' aPL, as well as other antibodies. Herein we describe the autoantigen properties, prevalence and clinical importance of 30 different antibodies in APS. Among the other antibodies characterizing APS are autoantibodies directed to platelets, glycoproteins, various coagulation factors, lamins, mitochondrial antigens and cell surface markers. Few of these autoantibodies are correlated with the presence of other antibodies, and some may have an additive role in the pro-thrombotic tendency of the syndrome. This autoantibody explosion might be important in early identification of the syndrome and its manifestations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171610     DOI: 10.1016/j.jaut.2007.11.011

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  29 in total

1.  Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.

Authors:  Jun Sang Yoo; Young Seo Kim; Hyun Young Kim; Hyuk Sung Kwon; Seong-Ho Koh; Sung Hyuk Heo; Bum Joon Kim; Cheryl D Bushnell; Dae-Il Chang
Journal:  J Neurol       Date:  2021-02-06       Impact factor: 4.849

2.  Pregnancy and catastrophic antiphospholipid syndrome.

Authors:  Jose A Gómez-Puerta; Jose Sanin-Blair; Claudio Galarza-Maldonado
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 3.  Clinical and laboratory features of the catastrophic antiphospholipid syndrome.

Authors:  Ljudmila Stojanovich; Dragomir Marisavljevic; Jozef Rovensky; Aleksandra Djokovich; Darina Kozáková; Nikola Milinic
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 4.  Atherosclerosis and autoimmunity.

Authors:  Eiji Matsuura
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

5.  Gastrointestinal-associated autoantibodies in different autoimmune diseases.

Authors:  Dana Ben-Ami Shor; Hedi Orbach; Mona Boaz; Arie Altman; Juan-Manuel Anaya; Nicola Bizzaro; Angela Tincani; Ricard Cervera; Gerard Espinosa; Ljudmila Stojanovich; Blaž Rozman; Stefano Bombardieri; Salvatore De Vita; Jan Damoiseaux; Danilo Villalta; Elio Tonutti; Renato Tozzoli; Ori Barzilai; Maya Ram; Miri Blank; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Am J Clin Exp Immunol       Date:  2012-05-25

6.  Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients.

Authors:  Renato Alberto Sinico; Ilaria Cavazzana; Monica Nuzzo; Monica Vianelli; Pietro Napodano; Patrizia Scaini; Angela Tincani
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

7.  The spectrum between antiphospholipid syndrome and systemic lupus erythematosus.

Authors:  Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2014-03       Impact factor: 2.980

Review 8.  Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse.

Authors:  Silvia Bucciarelli; Doruk Erkan; Gerard Espinosa; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

9.  Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome.

Authors:  R Weiss; A Bitton; L Nahary; M T Arango; I Benhar; M Blank; Y Shoenfeld; J Chapman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 10.  Revisiting Libman-Sacks endocarditis: a historical review and update.

Authors:  Jennifer L Lee; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.